Inamed gets breast implant setback; FDA revises guidance
This article was originally published in Clinica
Executive Summary
Inamed has said that it intends to forge ahead with plans to eventually market silicone gel implants in the US and is confident of gaining FDA approval, despite failing to win the agency's approval earlier this week. The company's statement comes hot-on-the-heels of the FDA's January 8 release of revised guidelines for breast implant manufacturers.